The federal Food and Drug Administration has issued draft guidance on the best practices for distributing scientific and medical publications including information about unapproved off-label uses of drugs and medical devices.
While doctors can prescribe drugs and medical devices for off-label uses, marketing drugs or medical devices for off-label uses is barred and often is cited by plaintiffs in mass-tort litigation as evidence of bad behavior by drug companies and medical-device manufacturers.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
